To print: Select File and then Print from your browser's menu --------------------------------------------------------------------------------------- Title: Adding Carvedilol Therapy Prevents Progression of Chronic Kidney Disease: Presented at ASN URL: http://www.pslgroup.com/dg/216C7E.htm Doctor's Guide November 6, 2007
By Bryan DeBusk, PhD SAN FRANCISCO, CA -- November 6, 2007 -- Patients with stage 3 chronic kidney disease (CKD) who receive carvedilol in addition to their other prescribed therapies are 29.8% less likely to progress to stage 4 CKD over a 3-year period. Naoyuki Nakao, MD, Clinician, Division of Nephrology and Dialysis, Kohnan Hospital, Kobe, Japan, reported the findings here at Renal Week 2007, the American Society of Nephrology (ASN) Annual Meeting. Dr. Nakao and colleagues randomised 245 patients with stage 3 or stage 4 CKD into two groups to receive placebo (n = 122) or 3.75 to 30 mg carvedilol (n = 123) three times a day. Patients were followed for 3 years to examine time of doubling of serum creatinine and time to progression of end-stage renal disease (ESRD). Following adjustments for baseline blood pressure, rate of daily urinary protein production, renal function, and diabetes, patients receiving carvedilol had a 0.70 relative risk for doubling serum creatinine and progressing to ERSD (95% confidence interval [CI], 0.56-0.80, P =.009). An additional reduction in heart rate was observed in the group receiving carvedilol (P =.01), but no difference was noted in blood pressure between the two groups. Dr. Nakao also noted that carvedilol significantly reduced the number of cardiovascular disease events despite the underlying CKD stage. Although the effects on progression to more severe CKD were primarily limited to individuals with stage 3 CKD, Dr. Nakao concluded that "carvedilol should be considered another tool for better management of those at high risk." [Presentation Title: A Randomized Trial of the B-Adrenergic Antagonist Carvediol in Chronic Kidney Disease (CCARE Trial). Abstract SA-FC039] --------------------------------------------------------------------------------------------- Copyright © 1999 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content. --------------------------------------------------------------------------------------------- This news story was printed from *Doctor's Guide to the Internet* located at http://www.docguide.com --------------------------------------------------------------------------------------- Return to News Story Page This site is maintained by webmaster@pslgroup.com Please contact us with any comments, problems or bugs. All contents Copyright (c) 1998 P\S\L Consulting Group Inc. All rights reserved.